CitiusTech Joins Covisint Certified Partner Program

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
CitiusTech Joins Covisint Certified Partner Program

DETROIT, July 2, 2014 (GLOBE NEWSWIRE) -- Covisint Corporation (Nasdaq: COVS ), a provider of a leading cloud engagement platform , today announced that CitiusTech, a leading provider of healthcare technology services and solutions has joined Covisint's Certified Service Partner Program. CitiusTech will help healthcare organizations and payers gain competitive advantage by leveraging the Covisint platform to enhance healthcare workflows and facilitate more seamless exchange of information across payers, providers, physicians and other stakeholders, thus significantly improving patient care and reducing healthcare costs.

"Our cloud platform is a key enabler to connecting healthcare and the transformation that is underway across the industry," said Covisint CEO Sam Inman. "CitiusTech's capabilities and people bring a wealth of healthcare knowledge and expertise, and having them join our services partner network strengthens the delivery of our platform in healthcare."

The partnership will focus on delivering Covisint services with support for reselling subscription services being rolled out later in the year. CitiusTech consultants will be trained and certified on Covisint technology and methodologies with Covisint providing dedicated support resources.

"We are really excited to partner with Covisint," said Rizwan Koita, CEO, CitiusTech. "Our joint vision of facilitating cloud capabilities for collaboration and engagement resonates strongly with the emerging needs of the healthcare industry."  

CitiusTech and Covisint have collaborated across several key engineering and professional services initiatives in healthcare over the past three years. The new partnership will enable clients to benefit from the strong health information exchange (HIE) platform capabilities of Covisint and the enterprise solution design and system integration capabilities of CitiusTech.

Covisint

Covisint provides the leading cloud engagement platform for creating and enabling new mission-critical external business processes.  Our solutions enable organizations to connect, engage, and collaborate with the critical external audiences that define their success -- including customers, business partners, and suppliers. Covisint allows its clients to establish a secure, reliable, integrated presence in the cloud, and offer the kind of engaging information experiences that people everywhere have come to expect. Learn more at www.covisint.com .

Follow us:

CitiusTech

CitiusTech is a specialist provider of healthcare technology services and solutions to healthcare IT vendors, providers, ACOs, health plans and life sciences companies. CitiusTech offers a wide range of healthcare technology services including healthcare software development, healthcare interoperability, Meaningful Use compliance, BI / analytics, care management and consumer health. With strong healthcare domain expertise across technologies, applications and standards, CitiusTech delivers best-in-class solutions with an unmatched cost advantage to global healthcare clients. For more information, visit www.citiustech.com .

Follow us:

Covisint Media Contact Brad Schechter 313.961.5290 For Sales and Marketing Information Covisint Corporation One Campus Martius Detroit, MI 48226 313-961-4100 http://www.covisint.com CitiusTech Media Contact Sujay Pal 877.248.4871 For Sales and Marketing Information CitiusTech Inc. 2 Research Way, 2nd Floor Princeton, NJ 08540 http://www.citiustech.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 445

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
HONGQI's EHS4 Launch in Europe: Bridging East and West

Updated Category News Views 222

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 198

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
BETR's Slide: Investors Face Big Losses, Leadership Shift

Updated Category News Views 216

BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 163

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 152

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 306

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 392

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 410

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 314

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading

Top 5 Most Recently Viewed Articles

Insights on Stocks: Applied Materials, Coupang, and Starbucks

Updated Category News Views 176

Market Highlights from CNBC's Final Trades In the latest episode of CNBC's “Halftime Report Final Trades,” Jim Lebenthal from Cerity Partners highlighted a compelling trade with Applied Materials, Inc. (NASDAQ: AMAT), suggesting it's one to watch closely in the current market environment. Applied Materials: Recent Developments Recently, applied materials found itself...

Continue Reading
Investors Urged to Take Action on Biohaven Ltd. Lawsuit

Updated Category News Views 101

Key Details for Biohaven Ltd. Investors Attention investors! If you've acquired securities of Biohaven Ltd. between certain dates, it's crucial to know about an ongoing class action lawsuit that may affect you. Now is the time to ensure your rights are protected. Why You Should Act Now The Rosen Law Firm has announced an important deadline for those who purchased Biohaven...

Continue Reading
ProPhase Labs Inc. Growth Update: Strategies & Innovations

Updated Category News Views 141

ProPhase Labs Inc. Update Overview Diamond Equity Research has recently published a significant update on ProPhase Labs Inc. (NASDAQ: PRPH), shedding light on the company’s strategic initiatives and innovations. This analysis explores ProPhase's evolving business model, its position within the industry, financial performance, and potential market risks. Growth...

Continue Reading
Donaldson Company Reports Record Sales and Ambitious 2026 Goals

Updated Category News Views 216

Donaldson Company Reports Outstanding Results for Fourth Quarter Donaldson Company (NYSE: DCI) has recently provided an impressive overview of its fourth-quarter and full-year fiscal 2025 performance. The company reported remarkable sales figures and notable earnings that reflect its ability to navigate market challenges effectively. With guidance for fiscal 2026 now in...

Continue Reading
Brandywine Realty Trust's 2024 Financial Performance Revealed

Updated Category News Views 189

Brandywine Realty Trust Reports Impressive Results for 2024 In a recent announcement, Brandywine Realty Trust (NYSE: BDN) showcased its financial and operational results for 2024, indicating strong performance across several metrics. As the company evaluates these results, it prepares for an even more promising outlook in 2025. Remarkable Achievements in 2024 Operational...

Continue Reading